Arrow Therapeutics, Ltd. Sustainability Profile
Arrow Therapeutics, Ltd., a prominent player in the biotechnology sector, is headquartered in Great Britain and operates extensively across Europe and North America. Founded in the early 2000s, the company has made significant strides in antiviral drug development, focusing on innovative therapies for infectious diseases. Arrow Therapeutics is renowned for its unique approach to drug discovery, leveraging cutting-edge technology to create targeted treatments that address unmet medical needs. Their core products include advanced antiviral compounds that have shown promise in clinical trials, setting them apart in a competitive market. With a strong commitment to research and development, Arrow Therapeutics has achieved notable milestones, positioning itself as a leader in the biotechnology industry. The company continues to expand its portfolio, aiming to improve patient outcomes and contribute to global health advancements.
DitchCarbon Score
How does Arrow Therapeutics, Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Arrow Therapeutics, Ltd.'s score of 79 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Arrow Therapeutics, Ltd., headquartered in Great Britain, currently does not report specific carbon emissions data, as no emissions figures are available. However, as a current subsidiary of AstraZeneca PLC, Arrow Therapeutics inherits significant climate commitments and initiatives from its parent company. AstraZeneca has set ambitious targets to reduce its carbon footprint, which include commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). These initiatives aim to align with global climate goals and promote transparency in emissions reporting. The SBTi targets and other climate initiatives are cascaded down to Arrow Therapeutics, ensuring that the subsidiary adheres to the same rigorous standards set by AstraZeneca. While specific reduction targets for Arrow Therapeutics are not detailed, the overarching commitments from AstraZeneca reflect a strong dedication to sustainability and climate action. This includes a focus on reducing Scope 1, 2, and 3 emissions across its operations. As Arrow Therapeutics continues to operate under the guidance of AstraZeneca's climate strategy, it is positioned to contribute to the broader goals of reducing greenhouse gas emissions and promoting environmental responsibility within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 298,498,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 322,319,000 | 000,000,000 | 000,000,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Arrow Therapeutics, Ltd.'s Industry?
How Carbon Intensive is Arrow Therapeutics, Ltd.'s Location?
Arrow Therapeutics, Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Arrow Therapeutics, Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
